Harmony Biosciences (HRMY) filed an 8-K on November 4, 2025, primarily to release financial results for the quarter ended September 30, 2025, accompanied by an Investor Presentation.
Q3 2025 Financial Performance & Guidance: Q3 Net Product Revenue was \(239.5M, reflecting 29% year-over-year growth driven by WAKIX®, which reached approximately 8,100 average patients with the highest quarterly patient additions since launch. Non-GAAP diluted EPS was \)1.08, and Non-GAAP Adjusted Net Income was $63.5M. The company maintains a strong balance sheet with cash, equivalents, and investments totalin
...